肾内科指南

订阅

MedSci主页 / 所有栏目 / 肾内科指南

急性疾病质量倡议共识会议对急性肾损伤生物标志物的建议：共识声明

2020-10-05 JAMA Netw Open . 2020 Oct 1;3(10):e2019209

急性肾损伤

重要性：在过去的十年中，已经确定并在临床试验中研究了急性肾损伤（AKI）的新生物标志物。需要有关如何最好地将它们纳入临床实践的指南。

中文标题：

急性疾病质量倡议共识会议对急性肾损伤生物标志物的建议：共识声明

英文标题：

Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement

发布机构：

发布日期：

2020-10-05

简要介绍：

重要性：在过去的十年中，已经确定并在临床试验中研究了急性肾损伤（AKI）的新生物标志物。需要有关如何最好地将它们纳入临床实践的指南。

目的：根据现有数据和专家共识，为临床医生和研究人员制定有关AKI生物标志物的建议。

证据审查：在第23届急性疾病质量倡议会议上，由23位重症监护，肾脏病学及相关专业的国际专家组成的会议召开，小组讨论了以下四个主要领域：（1）AKI风险评估； （2）AKI的预测与预防； （3）AKI的诊断，病因和管理； （4）AKI进展和肾脏恢复。文献搜索显示，在1965年至2019年5月之间发表了超过65 000篇文章。在经过改进的Delphi流程中，根据现有数据制定了建议和共识性声明，小组成员中有90％同意最终采用。使用建议分级，评估，发展和评估系统对建议进行分级。

调查结果：专家组针对生物标志物的使用制定了11项共识性声明，并提出了14项研究建议。关键建议是结合使用损伤和功能性生物标志物以及临床信息来识别高危患者组，提高AKI的诊断准确性，改善护理流程并协助AKI的管理。

结论和相关性：来自临床研究的最新证据支持在AKI的预防和管理中使用新的生物标记。知识方面仍存在巨大差距，需要进行更多研究。

相关资料下载：
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=955df1c0019931ce, title=急性疾病质量倡议共识会议对急性肾损伤生物标志物的建议：共识声明, enTitle=Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement, guiderFrom= JAMA Netw Open . 2020 Oct 1;3(10):e2019209, authorId=0, author=, summary=重要性：在过去的十年中，已经确定并在临床试验中研究了急性肾损伤（AKI）的新生物标志物。需要有关如何最好地将它们纳入临床实践的指南。, cover=, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Mon Oct 05 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<p>重要性：在过去的十年中，已经确定并在临床试验中研究了急性肾损伤（AKI）的新生物标志物。需要有关如何最好地将它们纳入临床实践的指南。</p> <p>目的：根据现有数据和专家共识，为临床医生和研究人员制定有关AKI生物标志物的建议。</p> <p>证据审查：在第23届急性疾病质量倡议会议上，由23位重症监护，肾脏病学及相关专业的国际专家组成的会议召开，小组讨论了以下四个主要领域：（1）AKI风险评估； （2）AKI的预测与预防； （3）AKI的诊断，病因和管理； （4）AKI进展和肾脏恢复。文献搜索显示，在1965年至2019年5月之间发表了超过65 000篇文章。在经过改进的Delphi流程中，根据现有数据制定了建议和共识性声明，小组成员中有90％同意最终采用。使用建议分级，评估，发展和评估系统对建议进行分级。</p> <p>调查结果：专家组针对生物标志物的使用制定了11项共识性声明，并提出了14项研究建议。关键建议是结合使用损伤和功能性生物标志物以及临床信息来识别高危患者组，提高AKI的诊断准确性，改善护理流程并协助AKI的管理。</p> <p>结论和相关性：来自临床研究的最新证据支持在AKI的预防和管理中使用新的生物标记。知识方面仍存在巨大差距，需要进行更多研究。</p>, tagList=[TagDto(tagId=2521, tagName=急性肾损伤)], categoryList=[CategoryDto(categoryId=14, categoryName=肾内科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2485, appHits=119, showAppHits=0, pcHits=649, showPcHits=2366, likes=0, shares=10, comments=5, approvalStatus=1, publishedTime=Tue Oct 20 09:57:50 CST 2020, publishedTimeString=2020-10-05, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Tue Oct 20 09:54:37 CST 2020, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 06:29:12 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1185385, encodeId=a41f1185385e8, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=60195579912, createdName=ms9000001722715168, createdTime=Mon Jan 17 23:43:28 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081854, encodeId=6cd410818545a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=383f5611431, createdName=ms3000001530930540, createdTime=Sun Dec 19 18:18:39 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076681, encodeId=bcc310e668117, content=正想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61f21445495, createdName=sandy_zjwx, createdTime=Fri Dec 03 23:05:01 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944557, encodeId=bd7394455e60, content=正想学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210621/bb78222cfbca429aa0fded99ce734910/d8b3cf2b1d9a432ea85113272a4fcde7.jpg, createdBy=2bfd5285536, createdName=14850e62m95暂无昵称, createdTime=Mon Mar 01 21:22:35 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918024, encodeId=0254918024f7, content=正要看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01f52568974, createdName=1257c336m18暂无昵称, createdTime=Tue Jan 19 12:53:26 CST 2021, time=2021-01-19, status=1, ipAttribution=)]
    2022-01-17 ms9000001722715168

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1185385, encodeId=a41f1185385e8, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=60195579912, createdName=ms9000001722715168, createdTime=Mon Jan 17 23:43:28 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081854, encodeId=6cd410818545a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=383f5611431, createdName=ms3000001530930540, createdTime=Sun Dec 19 18:18:39 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076681, encodeId=bcc310e668117, content=正想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61f21445495, createdName=sandy_zjwx, createdTime=Fri Dec 03 23:05:01 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944557, encodeId=bd7394455e60, content=正想学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210621/bb78222cfbca429aa0fded99ce734910/d8b3cf2b1d9a432ea85113272a4fcde7.jpg, createdBy=2bfd5285536, createdName=14850e62m95暂无昵称, createdTime=Mon Mar 01 21:22:35 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918024, encodeId=0254918024f7, content=正要看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01f52568974, createdName=1257c336m18暂无昵称, createdTime=Tue Jan 19 12:53:26 CST 2021, time=2021-01-19, status=1, ipAttribution=)]
    2021-12-19 ms3000001530930540

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1185385, encodeId=a41f1185385e8, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=60195579912, createdName=ms9000001722715168, createdTime=Mon Jan 17 23:43:28 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081854, encodeId=6cd410818545a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=383f5611431, createdName=ms3000001530930540, createdTime=Sun Dec 19 18:18:39 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076681, encodeId=bcc310e668117, content=正想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61f21445495, createdName=sandy_zjwx, createdTime=Fri Dec 03 23:05:01 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944557, encodeId=bd7394455e60, content=正想学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210621/bb78222cfbca429aa0fded99ce734910/d8b3cf2b1d9a432ea85113272a4fcde7.jpg, createdBy=2bfd5285536, createdName=14850e62m95暂无昵称, createdTime=Mon Mar 01 21:22:35 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918024, encodeId=0254918024f7, content=正要看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01f52568974, createdName=1257c336m18暂无昵称, createdTime=Tue Jan 19 12:53:26 CST 2021, time=2021-01-19, status=1, ipAttribution=)]
    2021-12-03 sandy_zjwx

    正想学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1185385, encodeId=a41f1185385e8, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=60195579912, createdName=ms9000001722715168, createdTime=Mon Jan 17 23:43:28 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081854, encodeId=6cd410818545a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=383f5611431, createdName=ms3000001530930540, createdTime=Sun Dec 19 18:18:39 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076681, encodeId=bcc310e668117, content=正想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61f21445495, createdName=sandy_zjwx, createdTime=Fri Dec 03 23:05:01 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944557, encodeId=bd7394455e60, content=正想学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210621/bb78222cfbca429aa0fded99ce734910/d8b3cf2b1d9a432ea85113272a4fcde7.jpg, createdBy=2bfd5285536, createdName=14850e62m95暂无昵称, createdTime=Mon Mar 01 21:22:35 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918024, encodeId=0254918024f7, content=正要看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01f52568974, createdName=1257c336m18暂无昵称, createdTime=Tue Jan 19 12:53:26 CST 2021, time=2021-01-19, status=1, ipAttribution=)]
    2021-03-01 14850e62m95暂无昵称

    正想学习一下

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1185385, encodeId=a41f1185385e8, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=60195579912, createdName=ms9000001722715168, createdTime=Mon Jan 17 23:43:28 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081854, encodeId=6cd410818545a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=383f5611431, createdName=ms3000001530930540, createdTime=Sun Dec 19 18:18:39 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076681, encodeId=bcc310e668117, content=正想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61f21445495, createdName=sandy_zjwx, createdTime=Fri Dec 03 23:05:01 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944557, encodeId=bd7394455e60, content=正想学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210621/bb78222cfbca429aa0fded99ce734910/d8b3cf2b1d9a432ea85113272a4fcde7.jpg, createdBy=2bfd5285536, createdName=14850e62m95暂无昵称, createdTime=Mon Mar 01 21:22:35 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918024, encodeId=0254918024f7, content=正要看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01f52568974, createdName=1257c336m18暂无昵称, createdTime=Tue Jan 19 12:53:26 CST 2021, time=2021-01-19, status=1, ipAttribution=)]
    2021-01-19 1257c336m18暂无昵称

    正要看

    0

相关指南

新型冠状病毒感染合并急性肾损伤诊治专家共识

中华医学会肾脏病学分会 · 2020-03-30

2017 共识指南：应用羧肽酶治疗高剂量甲氨蝶呤引起急性肾损伤以及甲氨蝶呤清除延迟患者

国外肿瘤科相关专家小组（统称） · 2017-10-27

2016 SIN立场声明：体外轻链去除技术治疗多发性骨髓瘤导致的急性肾损伤

意大利肾病学会(SIN,Italian Society of Nephrology) · 2016-10-18

2016 法国专家建议：围术期与ICU内急性肾损伤(不包括肾脏替代疗法)

法国麻醉和重症医学学会(SFAR,French Society for Anaesthesia and Intensive Care) · 2016-05-27

2014 ISPD指南：腹膜透析治疗急性肾损伤

国际腹膜透析协会(ISPD,International Society for peritoneal dialysis) · 2014-07-20

2013 NICE 169 急性肾损伤

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2013-08-28